Nature
Drug survival analysis of dupilumab and associated predictors in patients with atopic dermatitis in South Korea: single-center, retrospective study - Scientific Reports
The retrospective study demonstrated favorable dupilumab drug survival rates of 90.3%, 88.7%, 87.6%, and 87.6% after 1, 2, 3, and 4 years of treatment, respectively. In South Korea, dupilumab ...
5 days ago